Appointments: G1 Therapeutics, Breath Therapeutics, Fortress Biotech, Freeline Therapeutics, Enterome and Symic Bio
Executive Summary
GSK's former CEO Sir Andrew Witty has joined the board of directors of the oncology company, G1 Therapeutics. This week's roundup also includes CEO appointments by Fortress Biotech, Freeline Therapeutics and BridgeSat, in addition to various other high-level appointments by Nabriva Therapeutics, Caribou Biosciences, Symic Bio and Breath Therapeutics.